| Literature DB >> 25561935 |
Hakimeh Zali1, Mona Zamanian-Azodi1, Mostafa Rezaei Tavirani2, Alireza Akbar-Zadeh Baghban3.
Abstract
Different treatment strategies of Alzheimer's disease (AD) are being studied for treating or slowing the progression of AD. Many pharmaceutically important regulation systems operate through proteins as drug targets. Here, we investigate the drug target proteins in beta-amyloid (Aβ) injected rat hippocampus treated with Lavandula angustifolia (LA) by proteomics techniques. The reported study showed that lavender extract (LE) improves the spatial performance in AD animal model by diminishing Aβ production in histopathology of hippocampus, so in this study neuroprotective proteins expressed in Aβ injected rats treated with LE were scrutinized. Rats were divided into three groups including normal, Aβ injected, and Aβ injected that was treated with LE. Protein expression profiles of hippocampus tissue were determined by two-dimensional electrophoresis (2DE) method and dysregulated proteins such as Snca, NF-L, Hspa5, Prdx2, Apoa1, and Atp5a1were identified by MALDI-TOF/TOF. KEGG pathway and gene ontology (GO) categories were used by searching DAVID Bioinformatics Resources. All detected protein spots were used to determine predictedinteractions with other proteins in STRING online database. Different isoforms of important protein, Snca that exhibited neuroprotective effects by anti-apoptotic properties were expressed. NF-L involved in the maintenance of neuronal caliber. Hspa5 likewise Prdx2 displays as anti-apoptotic protein that Prdx2 also involved in the neurotrophic effects. Apoa1 has anti-inflammatory activity and Atp5a1, produces ATP from ADP. To sum up, these proteins as potential drug targets were expressed in hippocampus in response to effective components in LA may have therapeutic properties for the treatment of AD and other neurodegenerative diseases.Entities:
Keywords: Alzheimer's disease; Drug target; Hippocampus; Lavandula angustifolia; Proteomics
Year: 2015 PMID: 25561935 PMCID: PMC4277642
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Representative part of two-dimensional gel maps of proteins (N, Aβ and Aβ + LE) that MS-identified spots showing significant alterations in experimental groups are displayed in representative gels with corresponding identities.
Figure 2Known and predicted interactions of Snca (a), Hspa5 (b), Prdx2(c), Apoa1bp(d), Atp5a1(e) and NF-L(f) with other proteins. This functional protein association network was obtained by searching the STRING online database (http://string-db.org).
Differences related to statistically significant (P < 0.05) hippocampus proteome changes in N, Aβ and Aβ+ LE obtained by 2-DE gels.
|
|
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Aβ | Aβ+LE | |||||||||
| P37378 | SYU1 RAT | Alpha-synuclein, forms 1 and 3 | 1.22E+04 | 1.17E+04 | 2.46E+04 | 4.64E-08 | 2.1 | Cellular response to stress, microglial cell activation, regulation of receptor recycling, regulation of protein amino acid phosphorylation, positive regulation of neurotransmitter secretion, synaptic transmission, dopaminergic, myeloid leukocyte activation, oxidative phosphorylation, catecholamine metabolic process, fatty acid metabolic process, cellular ion homeostasis, | Fatty acid binding, phospholipid binding, cytoskeletal protein binding, protein transmembrane transporter activity, protein transporter activity,P-P-bond-hydrolysis-driven transmembrane transporter activity, tubulin binding, Hsp70 protein binding, dynein binding, tau protein binding, arachidonic acid binding, | Cell fraction, | Alzheimer's disease, Parkinson's disease |
| P37377 | SYU1 RAT | Alpha-synuclein, forms 1 and 3 | 1876.088 | 2471.546 | 4146.322 | 3.10E-08 | 2.2 | - | - | - | - |
| P06761 | GR78 RAT | Heat shock protein 5 | 2052.751 | 1565.22 | 3879.16 | 1.70E-07 | 2.5 | Cellular response to stress, anti-apoptosis, ER overload response, | Nucleotide binding,enzyme inhibitor activity, endopeptidase inhibitor activity, caspase inhibitor activity | Extracellular region, endoplasmic reticulum | Antigen processing and presentation, Prion diseases |
| P35704 | TDX1 RAT | Thioredoxin peroxidase 1 (thiol-specific antioxidant protein) | 6265.223 | 4560.234 | 1.26E+04 | 5.45E-06 | 2.8 | Cellular response to stress, MAPKKK cascade, activation of MAPK activity, response to reactive oxygen species, cell activation, response to molecule of bacterial origin, immune effector process, | Peroxidase activity, thioredoxin peroxidase activity, antioxidant activity, oxidoreductase activity, acting on peroxide as acceptor,peroxiredoxin activity, | Mitochondrion, cytosol, | |
| O09054 | APOA1_RAT | Apolipoprotein A-I | 874.559 | 1092.466 | 698.949 | 0.001 | 1.6 | Cellular response to stress, cell morphogenesis | Beta-amyloid binding, enzyme inhibitor activity, lipid transporter activity | Extracellular region, extracellular space, endoplasmic reticulum |
|
| P15999 | ATPA RAT | ATP synthase alpha chain, mitochondrial precursor (EC 3.6.1.34) (fragment) | 1365.504 | 2021.744 | 1577.425 | 9.54E-05 | 1.5 | Regulation of endothelial cell proliferation, oxidative phosphorylation, | ATPase, F1/V1/A1 complex, alpha/beta subunit, nucleotide-binding domain, | Mitochondrial proton-transporting ATP synthase complex, catalytic core F(1) | Oxidative phosphorylation, Alzheimer's disease, Parkinson's disease, Huntington's disease, |
| P19527 | NFL RAT | Neurofilament triplet L protein (68 kDa neurofilament protein) (NF-L) | 603.587 | 656.358 | 2204.352 | 1.82E-08 | 3.7 | Cellular response to stress, microtubule cytoskeleton organization, cell morphogenesis, protein complex assembly, | Structural molecule activity, enzyme binding, phospholipase binding, | Cytosol, cytoskeleton, intermediate filament, neurofilament, axon, TSC1-TSC2 complex, cell projection, neuron projection | Amyotrophic lateral sclerosis (ALS), |